An economic evaluation of a self-management programme of activity, coping and education for patients with chronic obstructive pulmonary disease

Chronic Respiratory Disease

Volumn 13, Issue 1, 2016, Pages 48-56

  Dritsaki, Melina ^a   Johnson Warrington, Vicki ^b   Mitchell, Katy ^b   Singh, Sally ^b   Rees, Karen ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

COPD; cost effectiveness analysis; cost utility analysis; education; RCT; self management

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; RESPIRATORY TRACT AGENT;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSULTATION; COPING BEHAVIOR; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RESEARCH COUNCIL DYSPNEA SCALE; MOTIVATIONAL INTERVIEWING; MULTICENTER STUDY (TOPIC); PATIENT EDUCATION; PHYSICAL ACTIVITY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE ASSESSMENT; SELF CARE; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ECONOMICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL;

ADAPTATION, PSYCHOLOGICAL; COST-BENEFIT ANALYSIS; FORCED EXPIRATORY VOLUME; HUMANS; PATIENT EDUCATION AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SELF CARE;

EID: 84957644842     PISSN: 14799723     EISSN: 14799731     Source Type: Journal    
DOI: 10.1177/1479972315619578     Document Type: Article

References (30)

1. The World Health Organisation. Available at: http://www.who.int/respiratory/copd/en/ (2012,. accessed 22 July 2015).
2. Zwerink M, Brusse-Keizer M, van der Valk PDLPM, et al. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; (3): CD002990.
3. Hurd S,. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000; 117 (2 suppl): 1S-4S.
4. Strassels S, Sullivan D, Smith DH,. Characterization of the incidence and cost of COPD in the US [abstract]. Eur Respir J 1996; 9 (suppl 23): 421s.
5. Wouters EF,. Economic analysis of the confronting COPD survey: overview of results. Respir Med 2003; 97 (suppl C): S3-S14.
6. Davies MJ, Heller S, Skinner TCM, et al.Diabetes education and self management for ongoing and newly diagnosed collaborative. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ 2008; 336 (7642): 491-495.
7. Effing T, Monninkhof EEM, van der Valk PP, et al. Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; (4): CD002990.
8. Kaptein Ad A, Fischer MJ, Scharloo M,. Self-management in patients with COPD: theoretical context, content, outcome, and integration into clinical care. Int J Chron Obstruct Pulmon Dis 2014; 9: 907-917.
9. Bourbeau J, Julien M, Maltais F, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Int Med 2003; 163 (5): 585-591.
10. Gallefoss F, Bakke PS,. How does patient education and self-management among asthmatics and patients with chronic obstructive pulmonary disease affect medication? Am J Respir Crit Care Med 1999; 160 (6): 2000-2005.
11. Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2010 Update. Available at: http://www.goldcopd.com (2010,. accessed 13 July 2015).
12. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update). NICE clinical guideline 101. London: National Institute for Health and Clinical Excellence (NHS Evidence accredited), 2010.
13. Monninkhof E, van der Valk P, van der Palen J, et al. Effects of a comprehensive self-management program in patients with chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 815-820.
14. Toy EL, Gallagher KF, Stanley EL, et al. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD 2010; 7 (3): 214-228.
15. Kdour MR, Kidney JC, Smyth BM, et al. Clinical pharmacy-led disease and medicine management programme for patients with COPD. Br J Clin Pharmacol 2009; 68 (4): 588-598.
16. Hoogendoorn M, van Wetering CR, Schols AM, et al. Is interdisciplinary community-based COPD management (INTERCOM) cost-effective? Eur Respir J 2010; 35 (1): 79-87.
17. Disler RT, Inglis SC, Davidson PM,. Non-pharmacological management interventions for COPD: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev 2013; (2): CD008427.
18. Mitchell KE, Johnson-Warrington V, Apps LD, et al. A self-management programme for COPD: a randomised controlled trial. Eur Respir J 2014; 44: 1538-1547.
19. Fletcher CM, Elmes PC, Fairbairn AS, et al. Significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959; 2 (5147): 257-266.
20. Apps LD, Mitchell KE, Harrison SL, et al. The development and pilot testing of the self-management programme of activity, coping and education for chronic obstructive pulmonary disease (SPACE for COPD). Int J COPD 2013; 8: 317-327.
21. Brooks R,. EuroQol: the current state of play. Health Policy 1996; 37 (1): 53-72.
22. National Institute for Health and Clinical Excellence. The social care guidance manual. London: NICE, 2013.
23. Dolan P, Gudex C, Kind P, et al. A social tariff for EuroQol: results from a UK general population survey (. Discussion paper 138). York: Centre for Health Economics, University of York, 1995.
24. Curtis L,. Unit costs of health and social care 2013: personal social services research unit. Kent: University of Kent, 2013.
25. Department of Health. Reference costs 2012. England: Department of Health, 2013.
26. British National Formulary. British National Formulary 63. UK: Pharmaceutical Press, 2012.
27. Hoch JS, Briggs AH, Willan AR,. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 2002; 11 (5): 415-430.
28. Glick HA, Doshi JA, Sonnad SS, et al. Economic evaluation in clinical trials. Oxford: Oxford University Press, 2007.
29. Earnshaw J, Lewis G,. NICE guide to the methods of technology appraisal: pharmaceutical industry perspective. Pharmacoeconomics 2008; 26: 725-727.
30. Effing T, Kerstjens H, van der Valk P, et al. Cost-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study. Thorax 2009; 64 (11): 956-962.